Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1956 1
1967 1
1982 2
1983 2
1984 1
1985 3
1986 2
1988 2
1990 1
1991 2
1992 3
1993 2
1994 2
1995 3
1996 1
1997 6
1998 2
1999 6
2000 3
2001 5
2002 3
2003 1
2004 5
2005 1
2006 1
2007 4
2008 5
2009 1
2010 2
2011 3
2012 3
2013 1
2014 1
2015 2
2016 1
2017 1
2018 1
2019 4
2020 3
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

89 results
Results by year
Filters applied: . Clear all
Page 1
Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial.
Wallace DJ, Furie RA, Tanaka Y, Kalunian KC, Mosca M, Petri MA, Dörner T, Cardiel MH, Bruce IN, Gomez E, Carmack T, DeLozier AM, Janes JM, Linnik MD, de Bono S, Silk ME, Hoffman RW. Wallace DJ, et al. Among authors: hoffman rw. Lancet. 2018 Jul 21;392(10143):222-231. doi: 10.1016/S0140-6736(18)31363-1. Lancet. 2018. PMID: 30043749 Clinical Trial.
Mixed connective tissue disease.
Hoffman RW, Greidinger EL. Hoffman RW, et al. Curr Opin Rheumatol. 2000 Sep;12(5):386-90. doi: 10.1097/00002281-200009000-00006. Curr Opin Rheumatol. 2000. PMID: 10990174 Review.
Baricitinib for systemic lupus erythematosus - Authors' reply.
Wallace DJ, Furie RA, Tanaka Y, de Bono S, Hoffman RW. Wallace DJ, et al. Among authors: hoffman rw. Lancet. 2019 Feb 2;393(10170):402-403. doi: 10.1016/S0140-6736(18)32749-1. Lancet. 2019. PMID: 30712893 No abstract available.
89 results